Package leaflet: Information for the patient

Mirtazapine Sandoz[®] orodispergeerbare tablet 15 mg, orodispergeerbare tabletten Mirtazapine Sandoz[®] orodispergeerbare tablet 30 mg, orodispergeerbare tabletten Mirtazapine Sandoz[®] orodispergeerbare tablet 45 mg, orodispergeerbare tabletten

mirtazapine

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

- 1. What [nationally completed name] is and what it is used for
- 2. What you need to know before you take [nationally completed name]
- 3. How to take [nationally completed name]
- 4. Possible side effects
- 5. How to store [nationally completed name]
- 6. Contents of the pack and other information

1. What [nationally completed name] is and what it is used for

[nationally completed name] is one of a group of medicines called **antidepressants**.

[nationally completed name] is used to treat depressive illness in adults.

nationally completed name] will take 1 to 2 weeks before it starts working. After 2 to 4 weeks you may start feeling better. You must talk to your doctor if you do not feel better or if you feel worse after 2 to 4 weeks. More information is in section 3 heading "When can you expect to start feeling better".

2. What you need to know before you take [nationally completed name]

Do not take [nationally completed name]:

- if you are **allergic** to mirtazapine or any of the other ingredients of this medicine (listed in section 6). If so, you must talk to your doctor as soon as you can before taking [nationally completed name].
- if you are taking or have recently taken (within the last two weeks) medicines called monoamine oxidase inhibitors (MAO-Is).

Warnings and precautions

Talk to your doctor or pharmacist before taking [nationally completed name]:

• if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking [nationally completed name] or other medicinal product(s).

Children and adolescents

[nationally completed name] should normally not be used for children and adolescents under 18 years because efficacy was not demonstrated. Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe [nationally completed name] for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed [nationally completed name] for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking [nationally completed name]. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioural development of [nationally completed name] in this age group have not yet been demonstrated. In addition, significant weight gain has been observed in this age category more often when treated with [nationally completed name] compared with adults.

Thoughts of suicide and worsening of your depression

If you are depressed you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.

You may be more likely to think like this:

- if you have previously had thoughts about killing or harming yourself.
- if you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.

 \rightarrow If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straightaway.

You may find it helpful to tell a relative or close friend that you are depressed, and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.

Also take special care with [nationally completed name]

if you have, or have ever had one of the following conditions.

 \rightarrow Tell your doctor about these conditions before taking [nationally completed name], if not done previously.

-seizures (epilepsy). If you develop seizures or your seizures become more frequent, stop taking [nationally completed name] and contact your doctor immediately;

-liver disease, including jaundice. If jaundice occurs, stop taking [nationally completed name] and contact your doctor immediately;

-kidney disease;

-heart disease, or low blood pressure;

-schizophrenia. If psychotic symptoms, such as paranoid thoughts become more frequent or severe, contact your doctor straightaway;

-manic depression (alternating periods of feeling elated/overactivity and depressed mood). If you start feeling elated or over-excited, stop taking [nationally completed name] and contact your doctor immediately;

-diabetes (you may need to adjust your dose of insulin or other antidiabetic medicines); -eye disease, such as increased pressure in the eye (glaucoma);

-difficulty in passing water (urinating), which might be caused by an enlarged prostate.

- -certain kinds of heart conditions that may change your heart rhythm, a recent heart attack, heart failure, or take certain medicines that may affect the heart's rhythm.
- if you develop signs of infection such as inexplicable high fever, sore throat and mouth ulcers.
 → Stop taking [nationally completed name] and consult your doctor immediately for a blood test.

In rare cases these symptoms can be signs of disturbances in blood cell production in the bone marrow. While rare, these symptoms most commonly appear after 4-6 weeks of treatment.

- if you are an elderly person. You could be more sensitive to the side-effects of antidepressants.
- serious skin reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of [nationally completed name]. Stop using and seek medical attention immediately if you notice any of the symptoms described in section 4 in relation to these serious skin reactions.
- if you have ever developed any severe skin reactions, treatment with [nationally completed name] should not be restarted.

Other medicines and [nationally completed name]

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Do not take [nationally completed name] in combination with:

• **monoamine oxidase inhibitors** (MAO inhibitors). Also, do not take [nationally completed name] during the two weeks after you have stopped taking MAO inhibitors. If you stop taking [nationally completed name], do not take MAO inhibitors during the next two weeks either. Examples of MAO inhibitors are moclobemide, tranylcypromine (both are antidepressants) and selegiline (used for Parkinson's disease).

Take care when taking [nationally completed name] in combination with:

- antidepressants such as SSRIs, venlafaxine and L-tryptophan, or triptans (used to treat migraine), buprenorphine (used to treat pain or opioid drug dependence), tramadol (a pain-killer), linezolid (an antibiotic), lithium (used to treat some psychiatric conditions), methylene blue (used to treat high levels of methemoglobin in the blood) and St. John's Wort Hypericum perforatum preparations (a herbal remedy for depression). In very rare cases [nationally completed name] alone or the combination of [nationally completed name] with these medicines, can lead to a so-called serotonin syndrome. Some of the symptoms of this syndrome are: inexplicable fever, sweating, increased heart rate, diarrhoea, (uncontrollable) muscle contractions, shivering, overactive reflexes, restlessness, mood changes, and unconsciousness. If you get a combination of these symptoms, talk to your doctor immediately.
- **the antidepressant nefazodone**. It can increase the amount of [nationally completed name] in your blood. Inform your doctor if you are using this medicine. It might be needed to lower the dose of [nationally completed name], or when use of nefazodone is stopped, to increase the dose of [nationally completed name] again.
- medicines for anxiety or insomnia such as benzodiazepines;

medicines for schizophrenia such as olanzapine; **medicines for allergies** such as cetirizine;

medicines for severe pain such as morphine.

In combination with these medicines [nationally completed name] can increase the drowsiness caused by these medicines.

• **medicines for infections;** medicines for bacterial infections (such as erythromycin); medicines for fungal infections (such as ketoconazole) and medicines for HIV/AIDS (such as HIV-protease inhibitors), **and medicines for stomach ulcers** (such as cimetidine).

In combination with [nationally completed name] these medicines can increase the amount of [nationally completed name] in your blood. Inform your doctor if you are using these medicines. It might be needed to lower the dose of [nationally completed name], or when these medicines are stopped, to increase the dose of [nationally completed name] again.

- medicines for epilepsy such as carbamazepine and phenytoin; medicines for tuberculosis such as rifampicin. In combination with [nationally completed name] these medicines can reduce the amount of [nationally completed name] in your blood. Inform your doctor if you are using these medicines. It might be needed to increase the dose of [nationally completed name], or when these medicines are stopped to lower the dose of
- [nationally completed name] again.
 medicines to prevent blood clotting such as warfarin.
 [nationally completed name] can increase the effects of warfarin on the blood. Inform your doctor if you are using this medicine. In case of combination it is advised that a doctor monitors your blood carefully.
- **medicines that may affect the heart's rhythm** such as certain antibiotics and some antipsychotics.

[nationally completed name] with food and alcohol:

You may get drowsy if you drink alcohol while you are taking [nationally completed name]. You are advised not to drink any alcohol.

You can take [nationally completed name] with or without food.

Pregnancy and breast-feeding:

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Limited experience with [nationally completed name] administration to pregnant women does not indicate an increased risk. However, caution should be exercised when used during pregnancy. If you use [nationally completed name] until, or shortly before birth, your baby should be supervised for possible adverse reactions. When taken during pregnancy, similar medicines (SSRIs) may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.

Driving and using machines:

[nationally completed name] can affect your concentration or alertness. Make sure these abilities are not affected before you drive or operate machinery. If your doctor has prescribed [nationally completed name] for a patient under 18 years make sure the concentration and alertness is not affected before participation in traffic (e.g. on bicycle).

[nationally completed name] contains aspartame, benzyl alcohol, sulphites and sodium:

15 mg orodispersible tablets:

This medicine contains 3 mg aspartame in each orodispersible tablet. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.

This medicine contains 0.047 mg of benzyl alcohol in each orodispersible tablet. Benzyl alcohol may cause allergic reactions. Ask your doctor or pharmacist for advice if you are pregnant or breast feeding or have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis").

30 mg orodispersible tablets:

This medicine contains 6 mg aspartame in each orodispersible tablet. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly. This medicine contains 0.093 mg of benzyl alcohol in each orodispersible tablet. Benzyl alcohol may

cause allergic reactions. Ask your doctor or pharmacist for advice if you are pregnant or breast feeding or have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis").

45 mg orodispersible tablets:

This medicine contains 9 mg aspartame in each orodispersible tablet. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.

This medicine contains 0.14 mg of benzyl alcohol in each orodispersible tablet. Benzyl alcohol may cause allergic reactions. Ask your doctor or pharmacist for advice if you are pregnant or breast feeding or have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis").

This medicine contains a very low amount of sulphites. This may rarely cause severe allergic (hypersensitivity) reactions and bronchospasm.

This medicine contains less than 1 mmol (23 mg) sodium in each orodispersible tablet, that is to say essentially 'sodium-free'.

3. How to take [nationally completed name]

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

How much to take

The recommended starting dose is 15 or 30 mg every day. Your doctor may advise you to increase your dose after a few days to the amount that is best for you (between 15 and 45 mg per day). The dose is usually the same for all ages. However, if you are an elderly person or if you have renal or liver disease, your doctor may adapt the dose.

When to take [nationally completed name]

 \rightarrow Take [nationally completed name] at the same time each day.

It is best to take [nationally completed name] as a single dose before you go to bed. However your doctor may suggest to split your dose of [nationally completed name] – once in the morning and once at night-time before you go to bed. The higher dose should be taken before you go to bed.

Take the orodispersible tablet as follows

Take your tablets orally.

1. Do not crush the orodispersible tablet

In order to prevent crushing the orodispersible tablet, do not push against the tablet pocket (Figure A).




Fig. A.

2. Tear off one tablet pocket

Each blister contains tablet pockets, which are separated by perforations. Tear off one tablet pocket along the dotted lines (Figure 1).





Fig. 1.

3. Peel off the lid

Carefully peel off the lidding foil, starting in the corner indicated by the arrow (Figures 2 and 3).



Page 6/12 1313-V22

Page 7/12 1313-V22

Juni 2024

Fig. 2.




Fig. 3.

4. Take out the orodispersible tablet

Take out the orodispersible tablet with dry hands and place it on the tongue. (Figure 4).



Fig. 4.

It will rapidly disintegrate and can be swallowed without water.

When can you expect to start feeling better

Usually [nationally completed name] will start working after 1 to 2 weeks and after 2 to 4 weeks you may start to feel better.

It is important that, during the first few weeks of the treatment, you talk with your doctor about the effects of [nationally completed name]:

 \rightarrow 2 to 4 weeks after you have started taking [nationally completed name], talk to your doctor about how this medicine has affected you.

If you still don't feel better, your doctor may prescribe a higher dose. In that case, talk to your doctor again after another 2 to 4 weeks. Usually you will need to take [nationally completed name] until your symptoms of depression have disappeared for 4 to 6 months.

If you take more [nationally completed name] than you should

Page 8/12 1313-V22

 \rightarrow If you or someone else has taken too much [nationally completed name], call a doctor straightaway. The most likely signs of an overdose of [nationally completed name] (without other medicines or alcohol) are **drowsiness**, **disorientation and increased heart rate**. The symptoms of a possible overdose may include changes to your heart rhythm (fast, irregular heartbeat) and/or fainting which could be symptoms of a life- threatening condition known as Torsade de Pointes.

If you forget to take [nationally completed name]

If you are supposed to take your dose once a day

• Do not take a double dose to make up for a forgotten dose. Take your next dose at the normal time.

If you are supposed to take your dose twice a day

- if you have forgotten to take your morning dose, simply take it together with your evening dose.
- if you have forgotten to take your evening dose, do not take it with the next morning dose; just skip it and continue with your normal morning and evening doses.
- if you have forgotten to take both doses, do not attempt to make up for the missed doses. Skip both doses and continue the next day with your normal morning and evening doses.

If you stop taking [nationally completed name]

 \rightarrow Only stop taking [nationally completed name] in consultation with your doctor.

If you stop too early, your depression might come back. Once you are feeling better, talk to your doctor. Your doctor will decide when treatment can be stopped.

Do not suddenly stop taking [nationally completed name], even when your depression has lifted. If you suddenly stop taking [nationally completed name] you may feel sick, dizzy, agitated or anxious, and have headaches. These symptoms can be avoided by stopping gradually. Your doctor will tell you how to decrease the dose gradually.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you experience any of the following <u>serious</u> side effects, stop taking mirtazapine and tell your doctor immediately.

Uncommon (may affect up to 1 in 100 people):

• feeling elated or emotionally 'high' (mania)

Rare (may affect up to 1 in 1,000 people):

• yellow colouring of eyes or skin; this may suggest disturbance in liver function (jaundice)

Not known (frequency cannot be estimated from the available data):

• signs of infection such as sudden unexplainable high fever, sore throat and mouth ulcers (agranulocytosis). In rare cases mirtazapine can cause disturbances in the production of blood cells

(bone marrow depression). Some people become less resistant to infection because mirtazapine can cause a temporary shortage of white blood cells (granulocytopenia). In rare cases mirtazapine can also cause a shortage of red and white blood cells, as well as blood platelets (aplastic anemia), a shortage of blood platelets (thrombocytopenia) or an increase in the number of white blood cells (eosinophilia).

- epileptic attack (convulsions)
- a combination of symptoms such as inexplicable fever, sweating, increased heart rate, diarrhoea, (uncontrollable) muscle contractions, shivering, overactive reflexes, restlessness, mood changes, unconsciousness and increased salivation. In very rare cases these can be signs of serotonin syndrome.
- thoughts of harming or killing yourself
- reddish patches on the trunk which are target-like macules or circular, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
- widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).

Other possible side-effects with mirtazapine are:

Very common (may affect more than 1 in 10 people):

- increase in appetite and weight gain
- drowsiness or sleepiness
- headache
- dry mouth

Common (may affect up to 1 in 10 people):

- lethargy
- dizziness
- shakiness or tremor
- nausea
- diarrhoea
- vomiting
- constipation
- rash or skin eruptions (exanthema)
- pain in your joints (arthralgia) or muscles (myalgia)
- back pain
- feeling dizzy or faint when you stand up suddenly (orthostatic hypotension)
- swelling (typically in ankles or feet) caused by fluid retention (oedema)
- tiredness
- vivid dreams
- confusion
- feeling anxious
- sleeping problems
- memory problems, which in most cases resolved when treatment was stopped.

Page 10/12 1313-V22

Uncommon (may affect up to 1 in 100 people):

- abnormal sensation in the skin e.g. burning, stinging, tickling or tingling (paraesthesia)
- restless legs
- fainting (syncope)
- sensations of numbress in the mouth (oral hypoaesthesia)
- low blood pressure
- nightmares
- feeling agitated
- hallucinations
- urge to move

Rare (may affect up to 1 in 1,000 people):

- muscle twitching or contractions (myoclonus)
- aggression
- abdominal pain and nausea; this may suggest inflammation of the pancreas (pancreatitis)

Not known (frequency cannot be estimated from the available data):

- abnormal sensations in the mouth (oral paraesthesia)
- swelling in the mouth (mouth oedema)
- swelling throughout the body (generalized oedema)
- localized swelling
- hyponatraemia
- inappropriate anti-diuretic hormone secretion
- severe skin reactions (dermatitis bullous, erythema multiforme)
- sleep walking (somnambulism)
- speech disorder
- Increased creatine kinase blood levels
- difficulty in passing urine (urinary retention)
- muscle pain, stiffness and/or weakness, darkening or discoloration of the urine (rhabdomyolysis)
- abnormally high levels of prolactin in the blood (and related symptoms like milky nipple discharge and swelling of breast tissue in males)

Additional side effects in children and adolescents

In children under 18 years the following adverse events were observed commonly in clinical trials: significant weight gain, hives and increased blood triglycerides.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in <u>Appendix V</u>. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store [nationally completed name]

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after "EXP". The expiry date refers to the last day of that month.

Do not store above 30°C. Store in the original package in order to protect from moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What [nationally completed name] contains

- The active substance is: Mirtazapine. Each orodispersible tablet contains 15 mg, 30 mg or 45 mg of mirtazapine.
- The other ingredients are: mannitol (E 421), povidone K30, crospovidone, silica colloidal anhydrous, aspartame (E 951), calcium stearate, orange flavour [maltodextrin, natural and artificial flavourings, dl-alpha-tocopherol, benzyl alcohol, sodium], peppermint flavour [maltodextrin, natural flavourings, dextrin, sulphites].

What [nationally completed name] looks like and contents of the pack

Orodispersible tablets: White to off-white, round, flat tablets with bevelled edges and plain on both sides.

[0711]

Aluminium/Aluminium blisters containing 6, 10, 14, 18, 20, 28, 30, 30 (unit dose), 48, 50, 56, 60, 84, 90, 96, 100 or 100 (unit dose) orodispersible tablets.

[0713]

Mirtazapine orodispersible tablet 15 mg: Aluminium/Aluminium blisters containing 6, 18, 20, 30, 48, 60, 90, 96, 100 or 250 orodispersible tablets

Mirtazapine orodispersible tablet 30 and 45 mg: Aluminium/Aluminium blisters containing 18, 30, 48, 60, 90, 96, 100 or 250 orodispersible tablets

Not all pack sizes may be marketed.

Houder van de vergunning voor het in de handel brengen en fabrikant

Houder van de vergunning voor het in de handel brengen

Sandoz B.V., Hospitaaldreef 29, 1315 RC Almere, Nederland

Fabrikanten

LEK d.d. Pharmaceuticals

Page 12/12 1313-V22

Verovškova 57 1526 Ljubljana Slovenië

Salutas Pharma GmbH Otto-von-Guericke-Allee 1 39179 Barleben Duitsland

Sandoz GmbH Biochemiestrasse 10 6250 Kundl Oostenrijk

In het register ingeschreven onder:

RVG 33376 (15 mg) RVG 33377 (30 mg) RVG 33378 (45 mg)

Dit geneesmiddel is geregistreerd in lidstaten van de EEA onder de volgende namen:

België:	Mirtazapine Sandoz 15 mg/30 mg/45 mg orodispergeerbare tabletten
Duitsland:	Mirtazapin HEXAL 15 mg/30 mg/45 mg Schmelztabletten
Hongarije:	Mirtazapin Sandoz 15 mg/30 mg/45 mg szájban diszpergálódó tabletta
Italië:	Mirtazapina Sandoz GmbH
Nederland:	Mirtazapine Sandoz orodispergeerbare tablet 15 mg/30 mg/45 mg,
	orodispergeerbare tabletten
Noorwegen:	Mirtazapin Sandoz 45 mg smeltetabletter
Portugal:	MIRTAZAPINA SANDOZ
Zweden:	Mirtazapin Sandoz 15 mg munsönderfallande tablett
Verenigd Koninkrijk:	Mirtazapine 15 mg/30 mg/45 mg Orodispersible Tablets

Deze bijsluiter is voor het laatst goedgekeurd in februari 2024